drugset / Trial / NCT04735796
Study of LM-102 in Subjects in Advanced Tumors
Non-randomizedSequentialSingle-blindTreatment
Summary
This is a phase Ⅰ, first-in-human, open-label, dose escalation study to evaluate the safety and tolerability, PK, immunogenicity and preliminary anti-tumor activity of LM-102 injection in subjects with CLDN18.2-positive advanced solid tumors.
Timeline
- Start
- 2021-05-27
- Primary completion
- 2022-05-19
- Completion
- 2022-05-19
Outcome
Outcome not reported
Stopped (Business): “Business strategy changed”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TECOTABART | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | TECOTABART | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | TECOTABART | Monoclonal antibody | 20 mg/kg | Intravenous |
| Subject | TECOTABART | Monoclonal antibody | 30 mg/kg | Intravenous |
| Subject | TECOTABART | Monoclonal antibody | 40 mg/kg | Intravenous |